Business Wire01.03.18
Glaukos Corporation, an ophthalmic medical technology company developing and commercializting breakthrough products and procedures designed to transform the treatment of glaucoma, has been issued a new U.S. patent.
Titled “Shunt Device and Method for Treating Ocular Disorders”, U.S. Patent No. 9,827,143 covers ocular devices and methods of surgically implanting the devices at least partially within Schlemm’s canal to facilitate the flow of aqueous humor.
“Our fundamental strategy at Glaukos is to develop micro-scale technologies that provide viable new treatment options for people suffering with glaucoma, one of the world’s leading causes of blindness,” said Thomas Burns, president and CEO. “This issued patent strengthens the protection of our inventions, further substantiates the proprietary nature of our technology and further expands our portfolio of more than 200 patents issued in the U.S. and major international markets.”
Glaukos pioneered micro-invasive glaucoma surgery (MIGS) and received U.S. Food and Drug Administration (FDA) approval for the iStent Trabecular Micro-Bypass, the market’s flagship MIGS device, in June 2012. Inserted through the trabecular meshwork and into Schlemm’s canal, the iStent is designed to lower intraocular pressure (IOP) by restoring the natural, physiological outflow of aqueous humor in patients with open-angle glaucoma. The iStent is currently approved for use in the United States in conjunction with cataract surgery. Made of surgical-grade non-ferromagnetic titanium that is coated with heparin, the iStent is approximately 1 mm long and 0.33 mm wide. Glaukos executives believe it is the smallest medical device ever approved by the FDA.
Glaucoma is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. There is no cure for the disease and reducing IOP is the only proven treatment. Based on analysis of population-based surveys, medical claims data and other statistics, the company estimates that there are approximately 5.4 million people in the United States with primary open-angle glaucoma, the most common form of the disease.
The iStent Trabecular Micro-Bypass Stent is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild-to-moderate open-angle glaucoma currently treated with ocular hypotensive medication.
Glaukos is based in San Clemente, Calif.
Titled “Shunt Device and Method for Treating Ocular Disorders”, U.S. Patent No. 9,827,143 covers ocular devices and methods of surgically implanting the devices at least partially within Schlemm’s canal to facilitate the flow of aqueous humor.
“Our fundamental strategy at Glaukos is to develop micro-scale technologies that provide viable new treatment options for people suffering with glaucoma, one of the world’s leading causes of blindness,” said Thomas Burns, president and CEO. “This issued patent strengthens the protection of our inventions, further substantiates the proprietary nature of our technology and further expands our portfolio of more than 200 patents issued in the U.S. and major international markets.”
Glaukos pioneered micro-invasive glaucoma surgery (MIGS) and received U.S. Food and Drug Administration (FDA) approval for the iStent Trabecular Micro-Bypass, the market’s flagship MIGS device, in June 2012. Inserted through the trabecular meshwork and into Schlemm’s canal, the iStent is designed to lower intraocular pressure (IOP) by restoring the natural, physiological outflow of aqueous humor in patients with open-angle glaucoma. The iStent is currently approved for use in the United States in conjunction with cataract surgery. Made of surgical-grade non-ferromagnetic titanium that is coated with heparin, the iStent is approximately 1 mm long and 0.33 mm wide. Glaukos executives believe it is the smallest medical device ever approved by the FDA.
Glaucoma is characterized by progressive, irreversible and largely asymptomatic vision loss caused by optic nerve damage. There is no cure for the disease and reducing IOP is the only proven treatment. Based on analysis of population-based surveys, medical claims data and other statistics, the company estimates that there are approximately 5.4 million people in the United States with primary open-angle glaucoma, the most common form of the disease.
The iStent Trabecular Micro-Bypass Stent is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild-to-moderate open-angle glaucoma currently treated with ocular hypotensive medication.
Glaukos is based in San Clemente, Calif.